CN109232585B - 一种多取代嘧啶并二吲哚酮衍生物的制备方法 - Google Patents
一种多取代嘧啶并二吲哚酮衍生物的制备方法 Download PDFInfo
- Publication number
- CN109232585B CN109232585B CN201811441040.4A CN201811441040A CN109232585B CN 109232585 B CN109232585 B CN 109232585B CN 201811441040 A CN201811441040 A CN 201811441040A CN 109232585 B CN109232585 B CN 109232585B
- Authority
- CN
- China
- Prior art keywords
- substituted
- polysubstituted
- derivative
- reaction
- crude product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical class C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000012043 crude product Substances 0.000 claims abstract description 8
- 239000004280 Sodium formate Substances 0.000 claims abstract description 6
- 239000004332 silver Chemical class 0.000 claims abstract description 6
- 229910052709 silver Inorganic materials 0.000 claims abstract description 6
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims abstract description 6
- 235000019254 sodium formate Nutrition 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims abstract description 5
- CZCXETFSJAOEHW-UHFFFAOYSA-N C(=O)N.CON1C=CC2=CC=CC=C12 Chemical class C(=O)N.CON1C=CC2=CC=CC=C12 CZCXETFSJAOEHW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- ZFGGCPZSSCNZSR-UHFFFAOYSA-N n-methoxy-1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)NOC)=CC2=C1 ZFGGCPZSSCNZSR-UHFFFAOYSA-N 0.000 claims description 2
- 238000010898 silica gel chromatography Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 7
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000741 silica gel Substances 0.000 abstract description 2
- 229910002027 silica gel Inorganic materials 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 238000013375 chromatographic separation Methods 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000003173 Drymaria cordata Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 description 1
- 229960003422 indobufen Drugs 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- PUYMDGCTMLYCLA-UHFFFAOYSA-N n,n-dimethyl-1h-indol-3-amine Chemical compound C1=CC=C2C(N(C)C)=CNC2=C1 PUYMDGCTMLYCLA-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了属于有机合成技术领域的一种多取代嘧啶并二吲哚酮衍生物的制备方法。所述方法为：向反应容器中，先后加入取代N‑甲氧基吲哚甲酰胺，取代3‑甲基吲哚，叔戊酸银和甲酸钠，加入溶剂六氟异丙醇，油浴100℃搅拌至反应1小时完毕后，使用旋转蒸发仪浓缩滤液得到粗产物，粗产物用硅胶柱层析分离得到目标化合物。本发明提供的多取代嘧啶并二吲哚酮衍生物的合成方法具有科学合理，方法简单，目标化合物产率较高，产物易于纯化等特点。其反应方程式如下：
Description
技术领域
本发明属于有机合成技术领域，具体涉及一种多取代嘧啶并二吲哚酮衍生物的制备方法。
背景技术
吲哚及其衍生物作为重要的杂环生物碱，大多具有显著的生理活性。目前，已上市的含吲哚结构的药物如：吲哚心安为受体阻断剂药，用于治疗心率失常、心绞痛和高血压。吲哚布芬为抗凝血药，具有显著的抗凝血性能。吲哚美辛为治疗风湿性疾病和多种关节炎的非甾体消炎药(J Nat Prod，1998，57(8):1053-1071.)。此外吲哚乙酸、吲哚-3-丁酸等是重要的植物生长调节剂(有机化学,2006,26:563-567)，能促进植物根和茎生长。3-二甲胺基吲哚是一类植物源农药，除对繁缕属杂草具有很强的抑制作用外(农药,2004,13:76)，还能使昆虫产生拒食性，具有开发为杀虫剂的潜力。
嘧啶酮类化合物也是一类重要的杂环化合物在很多领域都具有很好的应有前景，例如，抗癌和抗菌活性(J.Med.Chem.1987,30,1256-1261)。
作为嘧啶酮和吲哚两种含氮杂环的结合，嘧啶并二吲哚酮衍生物很可能具有这两种化合物的优势。鉴于嘧啶并二吲哚酮衍生物的广泛的生物活性和应用价值，发展一种实用有效地合成多取代嘧啶并二吲哚酮衍生物的新方法具有重要意义。
发明内容
本发明提供了一种多取代嘧啶并二吲哚酮衍生物的制备方法。
一种多取代嘧啶并二吲哚酮衍生物的制备方法，所述嘧啶并二吲哚酮衍生物具有式Ⅰ所示的结构：
R1取代基团选自氟、氯、溴、碘、甲氧基、甲基；R2选自甲基、乙基、异丙基、苄基；其特征在于，向反应器中，加入取代N-甲氧基吲哚甲酰胺，取代3-甲基吲哚，叔戊酸银和甲酸钠。在溶剂中搅拌反应完毕后，使用旋转蒸发仪浓缩得到粗产物，粗产物使用硅胶柱层析分离得到目标产物，其化学过程见反应式Ⅱ：
所述的取代N-甲氧基吲哚甲酰胺、取代3-甲基吲哚、叔戊酸银、和甲酸钠的摩尔比值为1：2：2：4。所述溶剂为六氟异丙醇,反应温度为100℃，反应时间为1h。
本发明的有益效果为：本发明提供的嘧啶并二吲哚酮衍生物的合成方法科学合理，提供了一种合成多取代嘧啶并二吲哚酮的新途径，通过本方法得到了具有多种取代基的嘧啶并二吲哚酮衍生物，其特点为：方法简单，目标化合物收率较高，产品易于纯化。
附图说明
图1为实施例1制备的化合物3aa的NMR图谱；
图2为实施例3制备的化合物3ca的NMR图谱；
图3为实施例7制备的化合物3ab的NMR图谱。
具体实施方式
下面结合附图和具体的实施例对本发明进一步详细的说明：
下述实施例中所述试验方法，如无特殊说明，均为常规方法；所述试剂和材料，如无特殊说明，均可从商业途径获得。
实施例1
1)嘧啶并二吲哚酮衍生物3aa的制备
向15mL厚壁耐压管中加入N-甲氧基吲哚甲酰胺1a(0.1mmol,38.0mg)、2a(0.2mmol,29.0mg)，叔戊酸银(0.2mmol,41.2mg)和甲酸钠(0.4mmol，27.2mg)加入六氟异丙醇(4mL)，在100℃的油浴中搅拌，反应1小时。反应完毕后，使用旋转蒸发仪除去溶剂得到粗产物，粗产物经柱层析分离(200-300目硅胶)(石油醚/乙酸乙酯＝15/1)，使用旋转蒸发仪除去溶剂，得到目标产物无取代嘧啶并二吲哚酮3aa，其收率为97％。
谱图解析数据3aa:
1H NMR(500MHz,CDCl3):δ8.48(d,J＝8.3Hz,1H),7.61(d,J＝7.8Hz,1H),7.46(d,J＝7.3Hz,1H),7.41–7.24(m,3H),6.94(t,J＝7.4Hz,1H),6.73(d,J＝7.9Hz,1H),6.70(s,1H),4.13(s,1H),3.34(s,3H),2.83(s,3H),1.73(s,3H).13C NMR(125MHz,CDCl3):δ152.2,150.2,136.0,130.2,129.0,128.7,128.3,125.1,124.9,123.1,120.5,119.5,115.9,109.3,69.5,69.1,64.2,33.5,18.4.HRMS(ESI-TOF,[M+Na]+):For C20H19N3O2,356.1375,Found:356.1374.
实施例2
用1b代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ba:
1H NMR(400MHz,CDCl3):δ8.42(dd,J＝9.1,4.7Hz,1H),7.47–7.43(m,1H),7.37–7.31(m,1H),7.27–7.22(m,1H),7.10(td,J＝9.2,2.6Hz,1H),6.94(td,J＝7.5,0.8Hz,1H),6.73(d,J＝7.9Hz,1H),6.65(s,1H),4.11(s,1H),3.33(s,3H),2.83(s,3H),1.73(s,3H).13CNMR(125MHz,CDCl3):δ160.4,158.5,152.1,150.0,132.3,130.4,130.3,129.8,129.7,128.2,124.9,119.6,116.9,116.8,113.1,112.9,109.3,108.8,106.0,105.9,69.3,64.3,33.6,18.4.HRMS(ESI-TOF,[M+H]+):For C20H18FN3O2,352.1461,Found:352,1462.
实施例3
用1c代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ca:
1H NMR(500MHz,CDCl3):δ8.40(d,J＝8.8Hz,1H),7.57(d,J＝1.8Hz,1H),7.45(d,J＝7.4Hz,1H),7.33(m,2H),6.94(t,J＝7.5Hz,1H),6.73(d,J＝7.9Hz,1H),6.64(s,1H),4.11(s,1H),3.32(s,3H),2.82(s,3H),1.73(s,3H).13C NMR(125MHz,CDCl3):δ152.2,149.9,134.3,130.3,130.2,130.2,128.8,128.2,125.3,125.0,120.1,119.7,116.9,109.4,108.4,69.4,64.3,33.6,18.5.HRMS(ESI-TOF,[M+H]+):For C20H18ClN3O2,368.1166,Found:368.1161.
实施例4
用1d代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3da:
1H NMR(500MHz,CDCl3):δ8.35(d,J＝8.8Hz,1H),7.74(s,1H),7.46(t,J＝7.4Hz,2H),7.34(t,J＝7.6Hz,1H),6.94(t,J＝7.4Hz,1H),6.73(d,J＝7.9Hz,1H),6.63(s,1H),4.11(s,1H),3.32(s,3H),2.82(s,3H),1.73(s,3H).13C NMR(125MHz,CDCl3):δ152.1,149.8,134.6,130.6,130.3,130.0,128.1,127.9,124.9,123.2,119.6,117.2,116.4,109.4,108.2,69.3,64.3,33.6,18.5.HRMS(ESI-TOF,[M+H]+):For C20H18BrN3O2,412.0661,Found:412,0651.
实施例5
用1e代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ea:
1H NMR(400MHz,CDCl3):δ8.24(d,J＝8.7Hz,1H),7.95(d,J＝1.5Hz,1H),7.64(dd,J＝8.7,1.7Hz,1H),7.48–7.42(m,1H),7.34(td,J＝7.8,1.3Hz,1H),6.94(td,J＝7.5,0.8Hz,1H),6.72(d,J＝7.9Hz,1H),6.61(s,1H),4.11(s,1H),3.32(s,3H),2.81(s,3H),1.73(s,3H).13C NMR(125MHz,CDCl3):δ152.1,149.9,135.2,133.6,131.3,130.4,129.7,129.4,128.1,125.0,119.7,117.7,109.4,108.0,100.0,87.2,69.3,64.3,33.7,18.5.HRMS(ESI-TOF,[M+H]+):For C20H18IN3O2,460.0522,Found:460.0516.
实施例6
用1f代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3fa:
1H NMR(500MHz,CDCl3):δ8.35(d,J＝9.0Hz,1H),7.44(d,J＝7.4Hz,1H),7.33(t,J＝7.7Hz,1H),7.05(s,1H),7.00(d,J＝10.2Hz,1H),6.93(t,J＝7.4Hz,1H),6.72(d,J＝7.9Hz,1H),6.61(s,1H),4.10(s,1H),3.87(s,3H),3.33(s,3H),2.83(s,3H),1.72(s,3H).13C NMR(125MHz,CDCl3):δ156.2,152.2,150.2,130.7,130.2,129.8,129.3,128.4,124.9,119.5,116.5,113.8,109.3,109.0,103.1,69.5,69.2,64.3,55.7,33.5,18.3.HRMS(ESI-TOF,[M+Na]+):For C21H21N3O3,386.1481,Found:386.1483.
实施例7
用1g代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ga:
1H NMR(400MHz,CDCl3):δ8.33(d,J＝8.5Hz,1H),7.47–7.42(m,1H),7.38(s,1H),7.33(td,J＝7.7,1.3Hz,1H),7.20(dd,J＝8.5,1.3Hz,1H),6.93(td,J＝7.5,0.8Hz,1H),6.72(d,J＝7.9Hz,1H),6.61(s,1H),4.10(s,1H),3.33(s,3H),2.82(s,3H),2.46(s,3H),1.72(s,3H).13C NMR(100MHz,CDCl3):δ152.2,150.4,134.2,132.7,130.2,129.3,128.8,128.5,126.5,124.9,120.4,119.5,115.5,109.3,109.0,69.6,69.2,64.3,33.6,21.4,18.4.HRMS(ESI-TOF,[M+Na]+):For C21H21N3O2,370.1531,Found:370.1531.
实施例8
用2b代替实例1中的2a,其他条件同实例1,实验结果见表1。
谱图解析数据3ab:
1H NMR(500MHz,CDCl3):δ8.47(d,J＝8.3Hz,1H),7.59(d,J＝7.8Hz,1H),7.44(d,J＝8.2Hz,1H),7.37(t,J＝8.4Hz,1H),7.33–7.25(m,2H),6.87(t,J＝7.3Hz,1H),6.67(t,J＝3.9Hz,2H),4.48(s,1H),3.48(dq,J＝14.4,7.1Hz,1H),3.36–3.23(m,4H),1.73(s,3H),1.12(t,J＝7.1Hz,3H).13C NMR(125MHz,CDCl3):δ150.2,135.9,130.1,129.0,128.7,128.2,125.1,125.0,123.0,120.5,118.5,115.9,109.0,108.7,69.2,64.6,64.2,38.2,18.3,8.7.HRMS(ESI-TOF,[M+Na]+):For C21H21N3O2,370.1531Found:370.1530.
实施例9
用2c代替实例1中的2a,其他条件同实例1,实验结果见表1。
谱图解析数据3ac:
1H NMR(500MHz,CDCl3):δ8.48(d,J＝8.3Hz,1H),7.60(d,J＝7.8Hz,1H),7.42(d,J＝7.4Hz,1H),7.38(t,J＝7.8Hz,1H),7.27(td,J＝14.2,13.3,7.7Hz,2H),6.85(dd,J＝7.4,5.3Hz,2H),6.67(s,1H),4.41(s,1H),3.76(p,J＝6.9Hz,1H),3.29(s,3H),1.67(s,3H),1.39(d,J＝7.1Hz,3H),1.20(d,J＝6.8Hz,3H).13C NMR(125MHz,CDCl3):δ150.1,149.6,136.1,129.7,128.9,128.3,125.2,125.0,123.0,120.5,118.2,115.8,110.1,110.0,69.1,65.4,64.1,46.3,21.0,18.2,15.3.HRMS(ESI-TOF,[M+Na]+):For C22H23N3O2,384.1688,Found:384.1687.
实施例10
用2d代替实例1中的2a,其他条件同实例1,实验结果见表1。
谱图解析数据3ad:
1H NMR(400MHz,CDCl3):δ8.48(d,J＝8.3Hz,1H),7.56(d,J＝7.8Hz,1H),7.46(d,J＝7.4Hz,1H),7.41–7.35(m,1H),7.30–7.26(m,2H),7.25–7.17(m,5H),6.89(t,J＝7.4Hz,1H),6.67–6.56(m,2H),4.74(d,J＝16.1Hz,1H),4.53(s,1H),4.18(d,J＝16.1Hz,1H),3.34(s,3H),δ1.73(s,3H).13C NMR(125MHz,CDCl3):δ151.3,150.1,137.3,136.0,130.2,128.9,128.6,128.5,127.7,127.3,127.2,125.1,123.1,120.6,118.8,115.8,109.6,109.1,69.3,66.4,64.2,49.2,18.3.HRMS(ESI-TOF,[M+Na]+):For C26H23N3O2,432.1688,Found:432.1684.
表1
Claims (2)
1.一种多取代嘧啶并二吲哚酮衍生物的制备方法，所述多取代嘧啶并二吲哚酮衍生物具有式Ⅰ所示的结构：
式Ⅰ中，R1取代基团选自氟、氯、溴、碘、甲氧基、甲基；R2取代基团选自甲基、乙基、异丙基、苄基；其特征在于，向反应器中，加入取代N-甲氧基吲哚甲酰胺，取代3-甲基吲哚，叔戊酸银和甲酸钠，在溶剂中搅拌反应完毕后，使用旋转蒸发仪浓缩得到粗产物，粗产物使用硅胶柱层析分离得到目标产物，其化学过程见反应式Ⅱ：
2.根据权利要求1所述的制备方法，取代N-甲氧基吲哚甲酰胺、取代3-甲基吲哚、叔戊酸银和甲酸钠的摩尔比值为1：2：2：4。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811441040.4A CN109232585B (zh) | 2018-11-29 | 2018-11-29 | 一种多取代嘧啶并二吲哚酮衍生物的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811441040.4A CN109232585B (zh) | 2018-11-29 | 2018-11-29 | 一种多取代嘧啶并二吲哚酮衍生物的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109232585A CN109232585A (zh) | 2019-01-18 |
| CN109232585B true CN109232585B (zh) | 2021-01-26 |
Family
ID=65073671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811441040.4A Active CN109232585B (zh) | 2018-11-29 | 2018-11-29 | 一种多取代嘧啶并二吲哚酮衍生物的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109232585B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307186A (en) * | 1979-08-02 | 1981-12-22 | Agfa-Gevaert Aktiengesellschaft | Photographic emulsion with stabilizer process for its preparation, photographic materials and process for the production of photographic images |
| CN103992326A (zh) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第二军医大学 | 吲哚并六氢吡嗪并喹唑啉酮类抗肿瘤化合物及其制备方法 |
| CN105481865A (zh) * | 2015-12-21 | 2016-04-13 | 广东工业大学 | 一种嘧啶并[1,6-a]吲哚杂环衍生物的制备方法 |
| CN108727385A (zh) * | 2018-07-14 | 2018-11-02 | 青岛科技大学 | 一种多取代二氢嘧啶并吲哚酮衍生物的制备方法 |
-
2018
- 2018-11-29 CN CN201811441040.4A patent/CN109232585B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307186A (en) * | 1979-08-02 | 1981-12-22 | Agfa-Gevaert Aktiengesellschaft | Photographic emulsion with stabilizer process for its preparation, photographic materials and process for the production of photographic images |
| CN103992326A (zh) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第二军医大学 | 吲哚并六氢吡嗪并喹唑啉酮类抗肿瘤化合物及其制备方法 |
| CN105481865A (zh) * | 2015-12-21 | 2016-04-13 | 广东工业大学 | 一种嘧啶并[1,6-a]吲哚杂环衍生物的制备方法 |
| CN108727385A (zh) * | 2018-07-14 | 2018-11-02 | 青岛科技大学 | 一种多取代二氢嘧啶并吲哚酮衍生物的制备方法 |
Non-Patent Citations (5)
| Title |
|---|
| Dearomative Indole (3 + 2) Reactions with Azaoxyallyl Cations−New Method for the Synthesis of Pyrroloindolines;Maria C.DiPoto et al.;《J.Am.Chem.Soc.》;20151112;第137卷;14861-14864 * |
| Dearomative Indole Cycloaddition Reactions of Aza-Oxyallyl Cationic Intermediates: Modular Access to Pyrroloindolines;Arjun Acharya et al.;《J.Am.Chem.Soc.》;20151112;第137卷;14858-14860 * |
| Silver-Catalyzed Radical Aminofluorination of Unactivated Alkenes in Aqueous Media;Zhaodong Li et al.;《J.Am.Chem.Soc.》;20130318;第135卷;4640-4643 * |
| Silver-Mediated Indole (4 + 2) Dearomative Annulation with N‑Radicals: A Strategy To Construct Heterocycle-Fused Indolines;Lin-Bao Zhang et al.;《ACS Catalysis》;20190117;第9卷;1680-1685 * |
| 银促进的N-中心自由基[4+2]环化反应研究;朱明辉;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20191115(第11期);B014-20 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109232585A (zh) | 2019-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Facile and efficient synthesis of a new class of bis (3′-indolyl) pyridine derivatives via one-pot multicomponent reactions | |
| Sridharan et al. | The first aza Diels–Alder reaction involving an α, β-unsaturated hydrazone as the dienophile: stereoselective synthesis of C-4 functionalized 1, 2, 3, 4-tetrahydroquinolines containing a quaternary stereocenter | |
| Li et al. | Efficient and mild one-pot three-component reaction to synthesize pyrano [3, 2-b] pyran derivatives in ionic liquid | |
| Zhang et al. | Facile synthesis of highly functionalized six-membered heterocycles via PPh3-catalyzed [4+ 2] annulations of activated terminal alkynes and hetero-dienes: scope, mechanism, and application | |
| Ma et al. | An intramolecular inverse electron demand Diels–Alder approach to annulated α-carbolines | |
| Sun et al. | Organocatalytic asymmetric one-pot sequential reaction: synthesis of highly substituted spirocyclohexanepyrazolones with six contiguous stereogenic carbons | |
| Stevens et al. | General methods of alkaloid synthesis. XI. Total synthesis of the sceletium alkaloid A-4 and an improved synthesis of (+-)-mesembrine | |
| CN109232585B (zh) | 一种多取代嘧啶并二吲哚酮衍生物的制备方法 | |
| CN108727385B (zh) | 一种多取代二氢嘧啶并吲哚酮衍生物的制备方法 | |
| CN104610267B (zh) | 无催化条件下高效的合成6-烷基吡唑并[1,5-c]喹唑啉骨架化合物的方法 | |
| JP7205059B2 (ja) | エボジアミンの製造方法 | |
| CN107868087B (zh) | 一种制备吡咯并吲哚类衍生物的方法 | |
| CN113234015B (zh) | 一种3-酰基二氢喹啉衍生物及其制备方法和应用 | |
| CN114507230B (zh) | 一种双环吡啶酮类衍生物、其合成方法及其用途 | |
| CN109851599B (zh) | 一种2-氨基苯并呋喃化合物的制备方法 | |
| CN109305970B (zh) | 1,7-二取代氨甲基-2,8-二羟基-Tr*ger’s Base催化剂制备及应用 | |
| KR101432427B1 (ko) | 요오드 촉매를 이용한 3-하이드록시-2-옥신돌 유도체의 효율적 합성방법 | |
| Hu et al. | Regioselective Synthesis of Phenoxathiin Derivatives under Transition-Metal-Free Conditions | |
| Spaeth et al. | Chiral Acyl Radicals Generated by Visible Light Enable Stereoselective Access to 3, 3-Disubstituted Oxindoles: Application toward the Synthesis of (–)-and (+)-Physovenine | |
| Cablewski et al. | N, N-Dialkyl-N′-Chlorosulfonyl Chloroformamidines in Heterocyclic Synthesis. IV. 3-Dialkylamino-1, 1, 8-trioxo-1H-1λ6-pyrano [3, 4-e][1, 4, 3] oxathiazines | |
| Usmanova et al. | Spontaneous formation of tricyclic lactones following the Castagnoli–Cushman reaction | |
| CN109369672B (zh) | 一种多取代环庚三烯衍生物的制备方法 | |
| CN114014838B (zh) | 一种化合物及其制备方法和应用 | |
| CN112745275B (zh) | 1,3,4-恶二唑杂环化合物的合成方法 | |
| Gao et al. | A facile synthesis of bisquinoline derivatives via the Williamson reaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240105 Address after: 256600 south side of xinyongxin Road, Binbei office, Bincheng District, Binzhou City, Shandong Province Patentee after: Shoujian Technology Co.,Ltd. Address before: No. 53, Zhengzhou Road, North District, Qingdao, Shandong Patentee before: QINGDAO University OF SCIENCE AND TECHNOLOGY |
|
| TR01 | Transfer of patent right |